AGF Investments Inc. grew its stake in CVS Health Corp (NYSE:CVS) by 1.9% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 324,514 shares of the pharmacy operator’s stock after buying an additional 6,000 shares during the period. AGF Investments Inc.’s holdings in CVS Health were worth $20,188,000 as of its most recent SEC filing.
Several other large investors also recently made changes to their positions in the business. Berkshire Asset Management LLC PA increased its stake in shares of CVS Health by 12.2% in the fourth quarter. Berkshire Asset Management LLC PA now owns 6,045 shares of the pharmacy operator’s stock worth $438,000 after purchasing an additional 657 shares during the period. Walter & Keenan Financial Consulting Co. MI ADV increased its stake in shares of CVS Health by 5.0% in the fourth quarter. Walter & Keenan Financial Consulting Co. MI ADV now owns 14,280 shares of the pharmacy operator’s stock worth $1,035,000 after purchasing an additional 680 shares during the period. Afam Capital Inc. increased its stake in shares of CVS Health by 1.5% in the third quarter. Afam Capital Inc. now owns 49,528 shares of the pharmacy operator’s stock worth $4,028,000 after purchasing an additional 731 shares during the period. Livingston Group Asset Management CO operating as Southport Capital Management increased its stake in shares of CVS Health by 1.6% in the fourth quarter. Livingston Group Asset Management CO operating as Southport Capital Management now owns 49,006 shares of the pharmacy operator’s stock worth $3,554,000 after purchasing an additional 752 shares during the period. Finally, Mission Wealth Management LP increased its stake in shares of CVS Health by 28.3% in the fourth quarter. Mission Wealth Management LP now owns 3,445 shares of the pharmacy operator’s stock worth $250,000 after purchasing an additional 759 shares during the period. 83.34% of the stock is owned by institutional investors.
CVS Health opened at $65.12 on Friday, according to Marketbeat Ratings. The company has a debt-to-equity ratio of 1.59, a quick ratio of 1.88 and a current ratio of 2.37. The company has a market cap of $66.71 billion, a price-to-earnings ratio of 11.04, a P/E/G ratio of 0.98 and a beta of 1.02. CVS Health Corp has a 1-year low of $60.14 and a 1-year high of $84.00.
CVS Health (NYSE:CVS) last released its quarterly earnings data on Wednesday, May 2nd. The pharmacy operator reported $1.48 earnings per share for the quarter, beating analysts’ consensus estimates of $1.39 by $0.09. The company had revenue of $45.69 billion for the quarter, compared to the consensus estimate of $45.77 billion. CVS Health had a return on equity of 17.45% and a net margin of 3.59%. The company’s quarterly revenue was up 2.6% on a year-over-year basis. During the same period in the previous year, the business earned $1.17 earnings per share. sell-side analysts predict that CVS Health Corp will post 6.99 EPS for the current year.
The business also recently disclosed a quarterly dividend, which was paid on Thursday, May 3rd. Shareholders of record on Monday, April 23rd were issued a dividend of $0.50 per share. This represents a $2.00 dividend on an annualized basis and a yield of 3.07%. The ex-dividend date of this dividend was Friday, April 20th. CVS Health’s payout ratio is 33.90%.
CVS has been the topic of a number of recent analyst reports. Needham & Company LLC upgraded CVS Health from a “buy” rating to a “strong-buy” rating and lifted their price objective for the stock from $88.00 to $100.00 in a research note on Tuesday, January 30th. Bank of America assumed coverage on CVS Health in a research note on Tuesday, February 27th. They issued a “buy” rating and a $91.00 price objective on the stock. Citigroup set a $77.00 price target on CVS Health and gave the company a “neutral” rating in a research note on Tuesday, February 13th. ValuEngine lowered CVS Health from a “buy” rating to a “hold” rating in a research note on Friday, February 2nd. Finally, Leerink Swann set a $85.00 price target on CVS Health and gave the company a “buy” rating in a research note on Friday, February 9th. Three investment analysts have rated the stock with a sell rating, six have assigned a hold rating, eleven have assigned a buy rating and two have assigned a strong buy rating to the company. CVS Health presently has an average rating of “Buy” and a consensus target price of $86.27.
In related news, Director C David Brown II acquired 10,000 shares of the firm’s stock in a transaction on Friday, May 4th. The shares were bought at an average cost of $61.99 per share, with a total value of $619,900.00. Following the completion of the acquisition, the director now owns 101,252 shares of the company’s stock, valued at $6,276,611.48. The acquisition was disclosed in a filing with the SEC, which is accessible through the SEC website. 0.53% of the stock is currently owned by insiders.
CVS Health Profile
CVS Health Corporation, together with its subsidiaries, provides integrated pharmacy health care services. It operates through Pharmacy Services and Retail/LTC segments. The Pharmacy Services segment offers pharmacy benefit management solutions, such as plan design and administration, formulary management, Medicare Part D services, mail order, specialty pharmacy and infusion services, retail pharmacy network management services, prescription management systems, clinical services, disease management programs, and medical pharmacy management services.
Receive News & Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related companies with MarketBeat.com's FREE daily email newsletter.